Pfizer’s final analysis shows 95% vaccine efficacy

Pfizer Inc. and BioNTech SE declared on Wednesday that their coronavirus vaccine applicant showed 95% efficacy in preventing the virus after final data analysis.

Meanwhile, the vaccine demonstrated over 94% effective among elderly participants in late-stage trials who are at high risk of suffering from a severe illness that may be generated by the virus.

Pfizer also unveiled that it intends to submit an application for emergency use authorization to the United States Food and Drug Administration (FDA) “within days.”